These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34383901)

  • 1. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
    Katsube T; Nicolau DP; Rodvold KA; Wunderink RG; Echols R; Matsunaga Y; Menon A; Portsmouth S; Wajima T
    J Antimicrob Chemother; 2021 Oct; 76(11):2902-2905. PubMed ID: 34383901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects.
    Kawaguchi N; Katsube T; Echols R; Wajima T; Nicolau DP
    J Clin Pharmacol; 2022 May; 62(5):670-680. PubMed ID: 34648652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects.
    Katsube T; Saisho Y; Shimada J; Furuie H
    J Antimicrob Chemother; 2019 Jul; 74(7):1971-1974. PubMed ID: 31220260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
    Caro L; Nicolau DP; De Waele JJ; Kuti JL; Larson KB; Gadzicki E; Yu B; Zeng Z; Adedoyin A; Rhee EG
    J Antimicrob Chemother; 2020 Jun; 75(6):1546-1553. PubMed ID: 32211756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection.
    Kawaguchi N; Katsube T; Echols R; Wajima T
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
    Petraitis V; Petraitiene R; Kavaliauskas P; Naing E; Garcia A; Georgiades BN; Echols R; Bonomo RA; Yamano Y; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0061822. PubMed ID: 36154614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions.
    Layios N; Visée C; Mistretta V; Denooz R; Maes N; Descy J; Frippiat F; Marchand S; Grégoire N
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205221. PubMed ID: 35099273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.
    Benítez-Cano A; Luque S; Sorlí L; Carazo J; Ramos I; Campillo N; Curull V; Sánchez-Font A; Vilaplana C; Horcajada JP; Adalia R; Bermejo S; Samsó E; Hope W; Grau S
    Crit Care; 2020 Feb; 24(1):55. PubMed ID: 32066497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.
    Skaar EP; Echols R; Matsunaga Y; Menon A; Portsmouth S
    Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):467-476. PubMed ID: 35025025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
    Saisho Y; Katsube T; White S; Fukase H; Shimada J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration.
    Möhlmann JE; van Luin M; Uijtendaal EV; Zahr N; Sikma MA
    Br J Clin Pharmacol; 2023 Dec; 89(12):3753-3757. PubMed ID: 37675616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.
    Katsube T; Echols R; Wajima T
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S552-S558. PubMed ID: 31724042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.
    Boselli E; Breilh D; Rimmelé T; Poupelin JC; Saux MC; Chassard D; Allaouchiche B
    Intensive Care Med; 2004 May; 30(5):989-91. PubMed ID: 14985960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
    Zhang Z; Patel YT; Fiedler-Kelly J; Feng HP; Bruno CJ; Gao W
    J Clin Pharmacol; 2021 Feb; 61(2):254-268. PubMed ID: 32949031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
    Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
    Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
    Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
    J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.